Parkman Healthcare Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Parkman Healthcare Partners’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-49,969	Closed	-$648K	–	75
2021 Q2	$648K	Buy	49,969 +388	+0.8%	+$4.94K	0.14%	77
2021 Q1	$644K	Sell	49,581 -39,922	-45%	-$579K	0.15%	80
2020 Q4	$1.24M	Sell	89,503 -40,809	-31%	-$594K	0.32%	71
2020 Q3	$1.92M	Buy	130,312 +24	+0%	+$348	0.51%	60
2020 Q2	$2.12M	Buy	130,288 +10,000	+8%	+$160K	0.6%	54
2020 Q1	$1.75M	Buy	120,288 +20,288	+20%	+$358K	0.81%	41
2019 Q4	$2.03M	Buy	+100,000	New	+$921K	0.58%	49

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KPWS

Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Parkman Healthcare Partners's AUPH Position: Q3 2021 in Review

Parkman Healthcare Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2021, closing a stake of 49,969 shares — an estimated $648K sold.

Parkman Healthcare Partners first reported a position in AUPH in Q4 2019 and held it in 7 quarters. The position peaked at $2.12M in Q2 2020. 166 funds tracked by Wall St. Rank hold AUPH as of Q3 2021.

Parkman Healthcare Partners reported no remaining Aurinia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Parkman Healthcare Partners sold 49,969 Aurinia Pharmaceuticals shares in Q3 2021, an estimated $648K.
Parkman Healthcare Partners first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 7 quarters.
Parkman Healthcare Partners's Aurinia Pharmaceuticals position peaked at $2.12M in Q2 2020.
166 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2021.

Based on Parkman Healthcare Partners's 13F filing for Q3 2021, filed 12 Nov 2021.